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Background: Ideally, the distribution of research funding for different types of cancer should be equitable with
respect to the societal burden each type of cancer imposes. These burdens can be estimated in a variety of ways;
“Years of Life Lost” (YLL) measures the severity of death in regard to the age it occurs, "Disability-Adjusted
Life-Years" (DALY) estimates the effects of non-lethal disabilities incurred by disease and economic metrics focus on
the losses to tax revenue, productivity or direct medical expenses. We compared research funding from the
National Cancer Institute (NCI) to a variety of burden metrics for the most common types of cancer to identify
mismatches between spending and societal burden.
Methods: Research funding levels were obtained from the NCI website and information for societal health and
economic burdens were collected from government databases and published reports. We calculated the funding
levels per unit burden for a wide range of different cancers and burden metrics and compared these values to
identify discrepancies.
Results: Our analysis reveals a considerable mismatch between funding levels and burden. Some cancers are
funded at levels far higher than their relative burden suggests (breast cancer, prostate cancer, and leukemia) while
other cancers appear underfunded (bladder, esophageal, liver, oral, pancreatic, stomach, and uterine cancers).
Conclusions: These discrepancies indicate that an improved method of health care research funding allocation
should be investigated to better match funding levels to societal burden.
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Economic costBackground
Cancer is the second leading cause of death in the Uni-
ted States, accounting for over 550,000 deaths in 2010
[1], and the fear of cancer is an ever-present specter in
society. Consequently, the government funds a consider-
able amount of medical research designed to understand
the processes involved in cancer progression with the
goal of improved treatments. Given that the total
amount of money devoted to improving public health is
limited, improvements in the allocation of funding can
benefit society at no additional cost. If the primary goal
of cancer research is to reduce the deleterious effects* Correspondence: ashley.carter@csulb.edu
Biological Sciences Department, California State University Long Beach, 1250
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distribution, and reproduction in any mediumcancer imposes on society and victims, two issues must
be addressed to enact a cancer research policy that best
achieves this goal. The issues are (1) the choice of one
or more appropriate metrics of cancer burden and (2)
the optimization of research spending with respect to
these burden metrics [2].
The most straightforward burden measurement is to
count raw mortality, the number of deaths caused by
cancer. Although this metric is the easiest to calculate
(death records are among the most reliable health
records) and the easiest to interpret, this metric alone is
incomplete. For example, one can argue that a disease
that killed 100,000 children demands more attention
than a disease that killed 100,000 people exclusively aged
80 years and older. Similarly, if two diseases are identicalentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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pensive due to inefficient treatment, more attention
should be given to improving the treatment of the more
costly disease.
Weighting the severity of death by the age a person is
killed is calculated by the metric broadly termed "Years
of Life Lost (YLL; sometimes also referred to as "Years
of Potential Life Lost", YPLL or "Potential Years of Life
Lost", PYLL). A number of variations of the YLL statistic
exist [3], including ones that cap life expectancy tables
at arbitrary values (essentially assigning no burden to
death at older ages). We believe that deaths to indivi-
duals age 65 or 70 are a burden on society so we con-
sider YLL values calculated from uncapped life
expectancies. YLL is calculated by subtracting the age at
death from the life expectancy based on the age bracket
of the deceased. Conceptually, a 20 year-old male dying
in 2010 with a projected life expectancy of 72.4 years
would have lost approximately 52.4 years due to cancer.
Alternatively, a 50 year-old male dying in 2010 with a
projected life expectancy of 67.55 years would have lost
only 17.55 years of life [4]. Actual YLL calculations are
more complex and based on detailed life tables for indi-
viduals at certain ages. Since older individuals have
already overcome some of their lifetime risk, their
remaining years of life is higher than merely subtracting
age at death from their original life expectancy at birth.
The YLL for an individual therefore never declines to
zero, but does decline as a person ages to reflect the
amount of additional time they would have been
expected to live.
In addition to YLL, many other health-based burden
metrics have been proposed (e.g., disability-adjusted life
years, DALY; Quality-adjusted life years, QALY; years
lost to disability, YLD). These values represent lost qual-
ity of life due to non-lethal disabilities by translating
these effects into years of life lost equivalents. For ex-
ample, surviving a condition but incurring severely
reduced mobility for the remaining years may result in
someone living 30 additional years being considered to
live 15 additional years instead due to the reduced qual-
ity of their life during those years. These metrics can be
useful, but are somewhat subjective [5] and have a num-
ber of technical and theoretical weaknesses [6]. We favor
the YLL metric because calculation is relatively straight-
forward; it weighs death at an early age higher than
death later in life, and is relatively free of arbitrary judg-
ment decisions. Actions that reduce the YLL will also
tend to reduce DALY and QALY values as well by virtue
of curing the disorders that cause the reduced quality of
life and increased disability measured by those statistics.
The use of DALYs is widespread however and previous
studies have shown that funding decisions may be driven
more strongly by DALY values than by mortality or YLLvalues [2,7] therefore we included an analysis of DALYs
in this study.
Additional metrics examining cancer burden attempt
to capture the economic costs. The YLL metric can be
adjusted to include years of working age lost and pro-
vides the economic cost to society based on lost tax rev-
enue and productivity (due to shortened careers and
time taken off for treatment). The direct financial cost
incurred by medical care for individuals undergoing
treatment can also be estimated. The first of these
metrics tends to weigh younger individuals higher, but
only after they achieve working age. This means that the
very young are assigned lower values, contrary to what
many members of society may believe. Estimating the
direct costs of medical care is complex as these values
may vary widely by region, personal income, and individ-
ual insurance status.
Once a metric has been chosen, improved funding al-
location can be achieved by distributing resources more
equitably according to this metric; according to this
logic, cancers with twice the burden should receive twice
the funding. Arguments for inequity in spending relative
to burden are equivalent to arguments for altering the
burden metric used. For example, an argument that
breast cancer deserves more funding than warranted (as
defined by one of the burden metrics above) may be
made due to the deep psychological importance and
sense of identity women attach to their breasts. This ar-
gument requires that psychological factors should be
added to the burden metric and shows the complexity
involved in considering the estimation of burden. Care-
ful attention to the metric used is essential because the
relative burdens incurred by different types of cancer are
likely to differ when using different metrics, sometimes
strikingly so [8]. Because various metrics may be favored
for different purposes, research spending should ideally
be compared to a number of different metrics to allow a
full consideration of cancer research policy to proceed.
A search of PubMed revealed a modest number of
published studies comparing research funding to societal
burden. Studies examining funding for broad categories
of disease include: Australian government funding and
grants awarded for a wide range of causes of death [9]
and specific cancers [10,11], Spanish government fund-
ing for a wide range of causes of death [12], US research
funding for a number of disorders by the National Cen-
ter for Complementary and Alternative Medicine [5], all
US public and private funding for a wide range of disor-
ders [13] and UK funding for cancer, heart disease,
stroke and dementia [14]. Only some of these studies fo-
cused on individual cancer types and compared research
effort to individual and societal burden [8,10,11,15]. The
discrepancies identified in these analyses differ from
those we identify and discuss below.
Table 1 Raw values used for analyses

















Bladder Blad 70530 14680 154.4 128.7 1023 3.466 1.977 22.6 10.52 2.19
Brain, ONS Br/cns 22020 13140 290.8 293 3.715 5.851 193.1 22.13 13.21
Breast Breast 209060 40230 761.3 612.5 1375 13.886 10.879 631.2 18.92 3.64
Cervix Cerv 12200 4210 104.7 114.1 73 1.425 1.808 76.5 24.87 8.58
Colon/rectum Co/rec 142570 51370 764.6 542.1 3101 12.155 12.802 270.4 14.88 5.36
Esophogus Esoph 16640 14500 214.2 122 386 1.071 — 30.5 14.77 12.87
Hogkin lymph. H lym 8490 1320 29.8 288.7** 1350* 10.168* 0.829 14.6 22.58 3.51
Kidney Kidney 58240 13040 195.7 — 685 3.058 3.633 90.0 15.01 3.36
Leukemia leuk 43050 21840 355.2 210.5 695 4.507 5.880 295.8 16.26 8.25
Liver Liver 24120 18910 292.2 137.8 278 — 4.638 72.6 15.45 12.11
Lung Lung 222520 157300 2369 1247.6 4238 10.315 38.953 281.9 15.06 10.65
Myeloma Myel 20180 10650 148.1 ** — — — 48.5 13.91 7.34
NH Lymphoma NHL 65540 20210 292.4 ** * * 5.755 122.4 14.47 4.46
Oral,pharnyx Oral 36540 7880 138 85.4 — — — 13.9 17.51 3.78
Ovary Ovary 21880 13850 248.8 145 507 4.379 2.945 112.3 17.96 11.37
Pancreas Panc 43140 36800 498.4 237.7 771 1.884 7.058 97.1 13.54 11.55
Prostate Pros 217730 32050 267.4 225 2294 9.862 3.538 300.5 8.34 1.23
Melanoma (skin) Melo 68130 8700 150.7 120.6 181 1.906 3.298 102.3 17.32 2.21
Stomach Stom 21000 10570 176 106.9 624 1.550 3.454 14.5 16.65 8.38
Testes Test 8480 350 11.8 — — — 0.472 6.3 33.71 1.39
Uterus Uter 43470 7950 122.8 75.5 340 2.330 1.101 14.2 15.45 2.82
Incidence, mortality, YLL, three measures of economic cost (Medicare payments, overall medical spending, and lost productivity), research funding by the NCI and calculated values for AYLL and YLLPI using data from
the table for the 21 cancers for which we had sufficient data. The symbol --- indicates that data for those values were not available, * indicates that for Medicare and National expenditure cost estimations the
categories "Hodgkin's lymphoma" and "non-Hodgkin's lymphoma" were combined in those reports, ** indicates that for for World Health Organization (WHO) DALY estimates the categories "Hodgkin's lymphoma",
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US based on recent data and presents a series of com-
parisons to the National Cancer Institute (NCI) research
funding levels. Several cancer types seem to be funded at
levels out of alignment with their respective societal bur-
dens. This disparity indicates an opportunity for improv-
ing the allocation of cancer research resources. We
examine a number of different comparisons; this ap-
proach is beneficial because it fosters a more compre-
hensive understanding of the overall issue.
Methods
The SEER Cancer Statistics Review 1975–2007 is pub-
lished by the National Cancer Institute and makes esti-
mations of national statistics based on direct information
from 26% of the US population [16]. That document
was used to obtain the values of incidence, mortality
and YLL for different cancers (their Table 1.1 and
Figure 1.19). Our own calculations (using raw data, not
reported) and those estimated in [17] are in very close
agreement with the SEER values (R2> 0.98 for both
comparisons). The "Average Years of Life lost" (AYLL)
statistic is calculated by dividing the YLL value by the
number of deaths for each cancer. The incidence and
































































Figure 1 NCI research funding relative to societal health cost. NCI rese
NCI funding for each cancer expressed as a percentage of overall funding
mortalities or (c) value of YLL as a percentage of the overall value for all 21values are estimates for 2007. Rather than match the
years for these values exactly, we elected to use the most
recent values available.
We used information available online from the World
Health Organization [18] to obtain the estimates of Uni-
ted States DALY values for most of the cancers used in
our analysis. Those records omitted liver cancer and
combined non-Hodgkin's and Hodgkin's lymphoma with
myeloma into a single category.
We examine an additional value which we term the
"Years of Life Lost Per Incidence" (YLLPI), which is cal-
culated by dividing the YLL by the number of new cases.
Whereas the AYLL estimates the years of life lost to
individuals that die, the YLLPI estimates the expected
years of life lost to an individual who is diagnosed with
cancer, including their chances of successful treatment
with no years of life lost. The YLLPI therefore includes
information about treatment efficiency (cancers with
high cure rates result in lower YYLPI values) and the po-
tential years of life lost (age at affliction enters the calcu-
lation by use of the YLL). We believe this metric best
represents the potential benefit accrued from research
by combining the potential for improved outcome (redu-
cing a high mortality rate) with the value of improved
outcome (favoring cures for the young over cures for thearch funding relative to societal health cost. Values are the amount of
















































Figure 2 NCI research funding relative to societal health cost as
measured by YLL. Dashed line indicates funding if resources are
equitably shared according to burden imposed by YLL, cancers
above the line receive more funding relative to YLL than expected
whereas cancers below the line receive less. Due to its extremely
large %YLL (approx. 30%) and relatively low funding (approx. 10%),
lung cancer is excluded from this plot and was not used in
these calculations.
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widely considered.
Values for research funding categorized by cancer type
were obtained from the NCI [19]. The categories for
cancer type are not identical in the NCI and SEER
sources described in the preceding paragraph. Hence,
some funding categories were combined in order to
match the SEER categories as follow: (i) brain, nervous
system and central nervous system categories were com-
bined and assigned to "brain, ONS"; (ii) kidney cancer
and kidney disease were combined and assigned to
"kidney"; (iii) leukemia and childhood leukemia were
combined and assigned to "leukemia", (iv) buccal cavity
and pharynx were combined and assigned to "oral,
pharyngeal".
Medical care for cancer patients represents a major
part of the economy and estimates of the direct cost of
cancer care can be made in different ways. Yarboff et al.
[20] used diagnosis and Medicare payment data from
2004 to estimate the 5-year cost of care for individuals
and calculated this for most of the cancers we consider
in this study (Their analysis omits estimates for mye-
loma, oral/pharyngeal and testes cancer and combines
Hodgkin's and non-Hodgkin's lymphomas). Their raw
numbers represent a subset of all health care spending
on these cancers and can't be used in direct calculations
with the values obtained from our other sources. For the
purpose of calculating the treatment cost of each cancer,
we do not expect relative costs to vary widely when pay-
ment is made by other sources. A second set of data for
costs was obtained directly from the NCI website [21].
Their figure LCO1 provides the estimated national
expenditures for cancer care in 2006 for most of the
cancers we consider in this study (Their figure omits
estimates for myeloma, oral/pharyngeal, liver and testes
cancer and combines Hodgkin's and non-Hodgkin's
lymphomas).
A measure of the economic burden incurred by lost
productivity due to cancer comes from estimating the
"present value of lifetime earnings" (PVLE) of all indivi-
duals that die from cancer in a given year [22]. This cal-
culation weighs working-age individuals higher than the
elderly (their remaining earnings are higher), weighs
males higher than females (males have higher average
incomes), and weighs racial and ethnic groups differently
(groups with lower average incomes are weighed lower
while those with higher average incomes are weighed
higher). Placing a dollar value on a life based on eco-
nomic calculations is routinely performed by govern-
mental agencies such as the Environmental Protection
Agency ($7.4 M in 2006 dollars; [23]) and the Federal
Highway Administration ($2.6 M in 1994 dollars; [24]).
We obtained PVLE values for individuals that die from
various cancer types from Table 2 of [22]; that sourceincluded values for most, but not all, cancers we con-
sider in this study (PVLE values for esophageal, myeloma
and oral/pharyngeal cancers were not reported).
A number of the calculations performed and values
plotted in the next section compare the percentage of
overall funding, cost or mortality for each cancer type to
one another. Unless otherwise noted, the overall fund-
ing, cost or mortality (including YLL, etc.) value is calcu-
lated from the sum of those listed and does not include
additional ones not plotted. For example, in comparisons
of %YLL and %Medicare costs for various cancers, the
overall YLL used for the %YLL calculations does not in-
clude myeloma, testes cancer and oral cancer as Medi-
care estimates were not available in our data source.
This discrepancy can result in slight differences in %YLL
values for each cancer in different comparisons, depend-
ing on which data was available. In each comparison,
we identify which cancers are included and excluded in
our analysis.
Due to its high incidence, prevalence and mortality
rates, lung cancer represents an outlier in many statis-
tical and social considerations of cancer prevention and
treatment funding. In comparative terms, lung cancer
causes more cases of cancer than any other type and
three times as many deaths as the next two most lethal
types of cancers (colo-rectal and breast). Meanwhile,
lung cancer receives less funding than breast, prostate
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tal cancer, which kills less than a third as many indivi-
duals. In absolute terms, lung cancer accounts for 32%
of cancer deaths while receiving 10% of cancer research
funding. Due to the extreme nature of incidence, preva-
lence and mortality values for lung cancer, some of the
analyses presented in this paper omit lung cancer be-
cause its inclusion would obscure the recognition of pat-
terns identified in the rest of the data.
Results
Raw data for the top 21 cancers are presented in Table 1.
This table provides data on the different variables used
for comparison in the study. Figure 1 shows the percent-
age of overall NCI research funding on these cancers
relative to the overall percentage of incidences, mortal-
ities and YLL expressed as a ratio - a general indication
of overfunding (ratio> 1) or underfunding (ratio< 1).
The ratios indicate large differences in funding per inci-
dent, mortality and YLL for different cancer types. The
cancers that appear to be the most overfunded depend
on the metric chosen, but similar discrepancies occur
multiple times. Considering incidence, overfunded can-
cers appear to be brain/CNS, cervical, leukemia, and
ovarian. Considering mortalities, overfunded cancers ap-
pear to be brain/CNS, breast, cervical, leukemia, and tes-










































0% 5% 10% 15% 20%
Figure 3 NCI research funding relative to societal health cost as
measured by DALYs. Dashed line indicates funding if resources are
equitably shared according to burden imposed by DALY, cancers
above the line receive more funding relative to DALY than expected
whereas cancers below the line receive less. Due to its extremely
large %DALY (approx. 30%) and relatively low funding (approx. 10%),
lung cancer is excluded from this plot and was not used in these
calculations.brain/CNS, breast, cervical, leukemia, melanoma, and
prostate. The cancers that appear to be the most consist-
ently underfunded across the different metrics are blad-
der, esophageal, lung, oral, stomach, and uterine cancers.
Figure 2 shows a plot of %NCI funding vs %YLL; data
points deviating from the 45 degree line of equitable
funding indicate over or under funding (according to a
goal of minimizing YLL) in absolute terms. Three cancer
types have extremely positive deviations indicating over-
funding (breast, leukemia, and prostate) and one other
has a moderately positive deviation (brain/CNS). The
negative deviations indicate that pancreatic cancer
appears the most underfunded, with bladder, colorectal,
esophageal, liver, oral, stomach, uterine cancers moder-
ately underfunded.
Figure 3 shows a plot of %NCI funding vs %DALY;
data points deviating from the 45 degree line of equit-
able funding indicate over or under funding (according
to a goal of minimizing YLL) in absolute terms. Similar
to figure 2, three cancer types have extremely positive
deviations indicating overfunding (breast, leukemia, and
prostate). The negative deviations indicate that bladder,
colorectal, esophageal, oral, pancreatic stomach and
uterine cancers appear underfunded.
Figure 4 indicates that NCI research funding at
present is not associated with YYLPI. Research efforts
are not directed at cancers for which the YLLPI statistic




































Figure 4 NCI research funding relative to YLLPI. Dashed line
indicates linear regression and the R2 of 0.0007 indicates that NCI
research funding is not associated with YYLPI. Removal of the
extreme value for breast cancer from this plot does result in a slight
























































Figure 5 NCI research funding relative to total number of
deaths. Dashed line indicates linear regression and the R2 of 0.0146
indicates virtually no relationship between the number of deaths
due to each cancer and the funding per death. Due to its extremely
large number of deaths (approx. 160,000) and relatively low funding
(approx. $1800 per death), lung cancer is excluded from this plot.
Removal of the extreme value for testes cancer from this plot
reverses the relationship (positive slope, R2 = 0.008), but it remains
non-significant.
Funding relative to YLL


























































0.0 0.5 1.0 1.5 2.0
Figure 6 NCI research funding relative to Medicare payment
costs [20] and YLL. Dashed lines indicate borders between regions
that are underfunded (%funding<% cost or %YLL) and overfunded
(%funding>% cost or %YLL). Several cancers have funding ratios
exceeding 2.0 for one axis or the other and are therefore
considerably overfunded according to the criteria corresponding to
that axis. To focus on underfunded cancers, those cancers (breast,
leukemia, melanoma, prostate, and brain/cns) are not depicted. Note
also that economic data for myeloma, oral cancer and testes cancer
was not available and the lymphoma data represents both
Hodgkin's and non-Hodgkin's lymphomas combined.
Carter and Nguyen BMC Public Health 2012, 12:526 Page 7 of 12
http://www.biomedcentral.com/1471-2458/12/526Figure 5 compares the funding per mortality to the
total number of mortalities. A situation where the quan-
tity of deaths influences funding may cause a mismatch
in funding prioritization. Due to the absence of a pattern
in this data (negative slope, R2 = 0.0146), high profile
cancers that cause more deaths do not appear to receive
more funding than expected based on the number of
overall deaths.
Figures 6, 7, 8 show the relationship between funding
relative to economic costs and funding relative to YLL.
Figure 6 calculates relative economic costs based on
Medicare payments using data in [20]. Figure 7 calcu-
lates relative economic costs based on overall national
spending on medical care for these conditions using data
in [21]. Figure 8 calculates relative economic costs based
on the total loss of productivity incurred by treatment
and deaths from these cancers (mainly from reductions
in lifetime earnings by decedents) using data in [22].
Cancers that appear in the lower left of these plots
(bladder, stomach, and uterine) are underfunded accord-
ing to both the YLL and economic metrics.
Discussion
The National Institutes of Health (NIH) has recom-
mended that research effort be compared to the societal
burden of that disease [2]. Our analysis indicates thatthe amount of NIH funding for research on a disease is
associated with the burden of the disease, but discrepan-
cies exist. Different measures of the burden of disease
yielded different conclusions about the degree to which
some cancer types were over or underfunded; these gen-
eral conclusions are in agreement with the study by
Gross et al. [2] from 1999 but also indicate that more
than a decade later these discrepancies persist.
For example, Figure 1 shows that stomach cancer
receives the least amount of funding relative to its bur-
den; stomach cancer receives less than 10% the amount
of funding, per death and YLL, of breast cancer. Simi-
larly, research funding to treat uterine cancer, per death
and YLL, is 10% the funding given to treat testes cancer.
Figures 1, 2, 3, 4 and 6, 7, 8 allow us to identify the
following cancers as funded at levels far below others
which incur similar costs to society: bladder, oral, uter-
ine, and stomach. A degree of underfunding also applies
to esophageal, liver, and pancreatic cancers. Given their
high YYLPI values, they represent promising areas for
potential gain compared to cancers that have already
achieved low mortality rates. Conversely, research on
breast cancer, leukemia, and prostate cancer appear to
be higher than justified relative to their burden on
Funding relative to YLL
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Figure 7 NCI research funding relative to estimated Total
National medical costs [21] and YLL. Dashed lines indicate
borders between regions that are underfunded (%funding<% cost
or %YLL) and overfunded (%funding>% cost or %YLL). Several
cancers have funding ratios exceeding 2.0 for one axis or the other
and are therefore considerably overfunded according to the criteria
corresponding to that axis. To focus on underfunded cancers, those
cancers (breast, leukemia and prostate) are not depicted. Note also
that economic data for liver cancer, myeloma, oral cancer and testes
cancer was not available and the lymphoma data represents both
Hodgkin's and non-Hodgkin's lymphomas combined.
Funding relative to YLL
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Figure 8 NCI research funding relative to economic costs
arising from lost productivity and earnings [22] and YLL.
Dashed lines indicate borders between regions that are
underfunded (%funding<% cost or %YLL) and overfunded (%
funding>% cost or %YLL). Several cancers have funding ratios
exceeding 2.0 for one axis or the other and are therefore
considerably overfunded according to the criteria corresponding to
that axis. To focus on underfunded cancers, those cancers (breast,
leukemia and prostate) are not depicted. Note also that
economic data for esophageal cancer, myeloma and oral cancer was
not available.
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summary, based on our data, we recommend that fund-
ing resources be directed away from breast cancer, pros-
tate cancer, and leukemia toward bladder, esophageal,
liver, oral, pancreatic, uterine, and stomach cancers.
To illustrate the type of redistribution we suggest, con-
sider Figure 2. Reducing the funding for leukemia re-
search to an equitable level with regard to YLL (from
11.70% of funding to 6.81%) would free more than
enough resources to raise bladder and uterine cancer
funding to equitable levels with regard to YLL (0.9% to
2.96% and 0.56% to 2.35% respectively), therefore creat-
ing a better overall distribution of funding relative to the
societal burden measured by YLL. As a second example,
plots 2 and 3 show that reducing breast cancer funding
alone to an equitable level would provide more funding
that could be used to raise several of these underfunded
cancers up to parity.
The use of DALYs has received much attention in the
prioritization of funding and studies have indicated that
funding is more tightly correlated with DALY values
than with incidence, mortality or YLL values [5]. Figure 3
illustrates a similar pattern of funding distribution rela-
tive to the different cancer types as seen in Figure 2 withthe exception that liver cancer appears more equitably
funded when using DALY values instead of YLL values.
Use of DALY values is controversial for two main rea-
sons [25,26]. First, the weights used are determined by
indirect methods rather than methods measuring impact
of the disabilities directly. Second, the estimation and
true cost of disability may vary in different regions and
within different subpopulations. Wealthier regions and
populations are better equipped to accurately estimate
the factors that go into the DALY weighting values and
may weight certain behavioral factors differently than
less wealthy groups. The conclusions of the analyses
using both the YLL and DALY values are similar there-
fore the controversial aspects of DALY valuations do not
pose a problem for our overall recommendations.
We believe that considering the "Years of Life Lost Per
Incidence" (YLLPI) is useful for making research deci-
sions. Research to treat cancer is often concerned with
improving the outcome of people afflicted. With the ex-
ception for special circumstances like the HPV vaccine
(which reduces the risk of cervical cancer), most NCI
funded research is aimed at reducing mortality instead
of incidence. If the number of cases is mainly due to fac-
tors like behavior and genetics that are hard to influence,
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vide the clearest identification of situations where
increased funding has the best potential to improve
treatment. This comparison does not include the num-
ber of individuals that may be affected by improved
treatment, but does estimate the "room for improve-
ment" per treatment. Cancers that kill younger indivi-
duals and have high mortality rates tend to have a
higher YLLPI. Marginal improvement in treatment for
these conditions may be a more realistic goal and pro-
vide the same or greater benefit than improvement in
conditions with low YLLPI because they already have
low mortality rates or tend to affect the elderly.
The economic costs of cancer are also part of the
overall consideration of research funding allocation. In
Figures 6, 7, 8 we compare funding relative to several
economic cost metrics and funding relative to YLL for
each cancer. The first two of these metrics (Medicare
payments and estimated medical care) measure direct
medical care costs. The third metric (lost productivity)
attempts to make a more comprehensive estimate of all
costs associated with cancer. Cancers in the lower left of
these plots appear to be underfunded according to both
the economic and YLL metrics. In addition to arguments
about reducing suffering, purely economic arguments
would favor increasing funding for cancers in the lower
left at the expense of decreased funding for cancers not
in these regions. This analysis indicates that the most
efficient changes in research allocation, from a pure-
ly financial perspective, involve reducing funding
for leukemia, melanoma, breast, and prostate cancers
while increasing funding for bladder, stomach, and
uterine cancers.
Comparison of our results with previous similar
studies reveals some similar conclusions and some
differences.
Incidence and mortality values were used in a Canad-
ian study by Branton [15] and in a strategic analysis
document published by the UK National Cancer
Research Institute [27]. For the Canadian data, colorectal
and lung cancers were identified as underfunded relative
to other cancers. The UK analysis identified leukemia,
ovarian and cervical cancers as overfunded whereas
lung, pancreatic, stomach, esophageal and bladder
cancers were identified as underfunded. These re-
sults generally agree with ours which may reflect
similar approaches to research science in the US, UK
and Canada.
Years of Life Lost values were used in studies of Aus-
tralian data. An analysis of overall Australian funding
per YLL showed that breast, cervical, leukemia, melan-
oma and prostate cancers were funded at far higher
levels than provided for bladder, brain, gall bladder,
lung/mesothelioma, kidney, lymphoma and pancreaticcancers [10]. Interestingly a separate analysis of Western
Australia showed similar results with the exception
that a large number of studies of mesothelioma were
funded [11], likely due to the history of asbestos mining
in the region.
Burnet et al. [8] performed a study of cancer funding
and societal burden as measured by YLL statistics Using
data from the UK (life expectancy data from 1990 life
tables and funding data from a 2002) to identify appar-
ent cases of funding discrepancy.
In their AYLL ("Average Years of Life Lost" which is
YLL per death) analysis they describe a "Cinderella" re-
gion with high AYLL and low funding to identify cancers
they believe deserve additional funds. However, focusing
on AYLL ignores the total number of cases and the per
incidence mortality rate in the burden completely. For
example, using their method, a cancer that kills a single
child each year would be placed within their "Cinderella"
region and be recommended for more funding. This ap-
proach would identify testes cancer as greatly under-
funded even though it has the lowest rate of incidence
and the lowest rate of mortality per incidence of the
cancers we examined, resulting in only 350 deaths in
2010. By focusing on AYLL alone, two of the four cancer
types they identify as underfunded (cervical cancer and
melanoma) are misidentified and appear overfunded
when using YLL as a metric. Furthermore, the six types
of cancer we identify as underfunded do not appear in
their "Cinderella" region of underfunded cancer types.
In their second analysis, comparing % overall funding
relative to % overall YLL, Burnet et al. [8] addresses
these issues and identifies several examples of funding
discrepancies. Figure 9 presents our values of %funding/
%YLL and those calculated using data in table 2 of Bur-
net et al. [8]. The general agreement of funding levels
for different cancers (R2 = 0.57 for the data shown in Fig-
ure 9) based on two distinct data sets (older UK vs more
recent US data) suggests that the conclusions we make
from this data are likely to be robust. A number of can-
cers (bladder, esophageal, lung, pancreatic, stomach, and
uterine) are identified as underfunded in both studies.
Various societal and cancer specific factors may ac-
count for some of the discrepancies observed.
Consideration of the data and discussions with medical
professionals lead us to believe that the relatively high
level of funding for breast cancer is due to the organized
efforts of women’s groups and charitable organizations
to raise awareness and concern about the burden caused
by this cancer. Similar efforts by women's groups may
account for the relatively high level of funding for cer-
vical cancer. Given this, we are unsure why uterine can-
cer exhibits lower than expected rates of funding.
Funding for lung cancer is quite low given its cost,























0.0 0.5 1.0 1.5 2.0 2.5 3.0











































Figure 9 Comparison of research funding relative to YLL as
reported for the UK [8] and in this study for the US. Dashed
lines indicate borders between regions that are underfunded (%
funding<% cost or %YLL) and overfunded (%funding>% cost or %
YLL). Cancers identified with triangles are those named in the text
(and abstract) of Burnet et al. [8] as lying in a "Cinderella" region
indicative of underfunding. Several cancers are identified as
underfunded in both studies, but only two of the "Cinderella" region
cancers appear underfunded according to the UK data and none are
underfunded according to our US data. Data for for Hodgkin's
lymphoma, liver cancer, oral cancer and testes cancer are not
plotted as they were not included in the UK data [8]. Due to its
extremely large ratio in the UK study (approx. 5.83) leukemia is
excluded from this plot although the values were used in the
calculation of the relative funding and YLL values for the remaining
cancer types.
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[15]. The levels of funding for liver cancer (2.6% of fund-
ing compared to 3.8% of deaths and 3.8% of YLL) and
oral cancer (0.5% of funding compared to 1.6% of deaths
and 1.8% of YLL) may also be influenced by this “blame
the victim” prejudice (Hepatitus B infection and alcohol-
ism contribute to liver cancer risk and chewing tobacco
contributes to oral cancer risk). However, this rationale
does not appear to be consistently applied. Cervical can-
cer is largely attributable to the HPV virus and the risk
of skin cancer can be greatly reduced by the application
of sunblock; in both cases, cancer patients are not
typically blamed for their personal actions. In fact, the
per-death research funding for cervical and skin can-
cers are both in the top 6 of our 21 examined can-
cers (Figure 1b) and cervical cancer has the highest
per-mortality research spending rate, indicating a
prioritization of research. Morally, if we decide that it is
appropriate for cancer victims to receive blame forcancers that result as a consequence of their actions,
funding for cervical and skin cancers should be reduced
in lieu of increased funding for other cancers. Alterna-
tively, if we decide that it is morally unacceptable to
place blame on cancer victims for poor lifestyle choices,
funding for lung, liver, and oral cancers should be
increased to levels comparable to other cancers relative
to their burden.
Although we examined the major source of research
funding provided by government, our study did not
examine the research effort conducted by commercial
entities and is therefore a partial view of the overall
funding landscape. The main reason we omitted re-
search funding by private entities is because the realloca-
tion decisions we suggest in this paper are guided by the
goal of reducing societal burden; private research entities
are motivated by financial concerns and the burdens
analysed in this paper are therefore less relevant for their
decision making processes. An interesting point arises
however when considering the approach taken by private
entities. Private research will tend to focus on the types
of cancer with the largest potential profit and private
funding will therefore be higher for more common can-
cers which create a larger market. Several of the cancers
we identified as overfunded are just these more common
types (breast, prostate, leukemia) and some of the ones
we identified as underfunded are relatively rare (oral,
uterine, stomach) and we expect that market forces will
tend to exacerbate these discrepancies in the private sec-
tor. For this reason we feel that governmental priorities
should lean on the side of favoring research for cancers
that are more rare when societal burden is similar.
Another factor that may account for the degree of
overfunding for certain cancers may be the existence
positive feedback cycles. As progress is made on one
type of cancer, successful researchers publish papers that
attract new funds and inspire students to follow their
footsteps. This progression leads to new discoveries and
the preparation of more sophisticated proposals and
studies [28]. For example, consider two hypothetical re-
search communities where the first develops cancer
treatments leading to high cure rates (e.g., 99%) and the
second develops fewer treatments with lower cure rates
(e.g., 40%). Clearly the potential for improvement is
higher in the second community. However, the success
rate of the first community may outshine the second
and attract more funding. This misallocation of
resources may have occurred in the case of leukemia re-
search. Branton [15] notes that hematopoietic cancers
attracted considerable attention and funding for treat-
ment. These cancers now have among the highest sur-
vival rates. If the societal dynamic we just described is a
potential cause of the non-equitable distribution of re-























Figure 10 Hypothetical relationships between research effort (I.
E., dollars) and results (metric unspecified). If each dollar spent
generates results that lead to the same decrease in burden then the
relationship between effort and results would be a linear one (solid
line). Positive synergistic effects would cause results, per dollar, to
increase with the total funding amount (dotted line). Negative
synergistic effects would cause results, per dollar, to decrease with
the total funding amount (dashed line). Which of these relationships
is likely to be true is unclear, but each leads to different optimal
approaches for the distribution of research effort.
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be warranted.
Conversely, targeted focus on specific cancers may be
beneficial depending on the nature of the relationship
between research effort and results. In our study we as-
sume a linear relationship between effort and result, but
other relationships may exist (Figure 10). For example, if
research efforts have a positive synergistic effect (where
each additional dollar leads to a magnified result), the
optimal strategy would be to concentrate funding in
fewer cancers and shift the focus as each cancer gains
improved treatments. Positive synergistic activities can
come from increasing the diversity of research plans and
funding high-risk high reward approaches that would
otherwise not be tried. On the other hand, if a negative
synergistic effect occurs where each additional dollar
spent leads to proportionally smaller results, the optimal
strategy would be to spread funding across cancers more
equitably, regardless of societal burden. Negative syner-
gistic effects can come from additional funding being
allocated to projects that are similar to previous ones
and offer marginal novelty or potential for benefit. In
light of this, examining the relationship between funding
and results to identify the type of synergistic relationship
in practice may prove highly beneficial.Currently, the NIH research funding decision process
has two stages. The initial stage is the scientific review
of the proposed study addressing significance, approach,
and innovation. This stage generates ranking based on
purely scientific factors. The second stage considers
additional criteria, including public health priorities
such as quality of life or health disparities. We believe
studies like ours can enhance the second stage of
this process by recognizing cancers that deserve more
attention and improving the allocation of limited re-
search resources.
Many may feel that reductionism to numbers in the
realms of human suffering and death is cold and heart-
less and a number of researchers have discussed contro-
versies associated with setting funding priorities based
on measures of burden [5-7,25,26]. We strongly believe
that funding decisions should take burden into account;
since total funding is limited, only by objectively identi-
fying disorders that receive non-optimal funding can we
adjust our efforts to minimize the overall cost of disease.
Our approach has led us to identify breast cancer, pros-
tate cancer, and leukemia as funded at levels higher than
other cancers relative to their societal burden and blad-
der, esophageal, liver, oral, pancreatic, stomach, and uter-
ine cancers as relatively underfunded.
Conclusions
We analyzed research funding distribution for different
cancers in the United States. Based on burden metrics
including incidences, mortalities, economic costs, and
Years of Life Lost (YLL) we identified inequities in can-
cer research funding relative to burden. Overfunded can-
cers include breast cancer, prostate cancer, and
leukemia; underfunded cancers include bladder, esopha-
geal, liver, oral, pancreatic, stomach, and uterine cancer.
We recommend redistribution from overfunded cancers
to underfunded cancers to improve the effectiveness of
cancer research funding.
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